Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO).

Auteurs : Fontaine C, Renard V, Van den Bulk H, Vuylsteke P, Glorieux P, Dopchie C, Decoster L, Vanacker L, de Azambuja E, De Greve J, Awada A, Wildiers H
Année : 2019
Journal : Breast Cancer Res Treat
Volume : 176
Pages : 607-615

CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an <i>ESMO Open-Cancer Horizons</i> pro and con discussion.

Auteurs : Awada A, Gligorov J, Jerusalem G, Preusser M, Singer C, Zielinski C
Année : 2019
Journal : ESMO Open
Volume : 4
Pages : e000565

Predictive factors for cancer-associated thrombosis in a large retrospective single-center study.

Auteurs : Haltout J, Awada A, Paesmans M, Moreau M, Klastersky J, Machiels G, Ignatiadis M, Kotecki N
Année : 2019
Journal : Support Care Cancer
Volume : 27
Pages : 1163-1170

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Auteurs : Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, OShaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J
Année : 2019
Journal : Ann Oncol
Volume : 30
Pages : 397-404

Long-Term Clinical Outcome and Survivorship Issues of High Grade Bone Sarcomas

Auteurs : Closset C, Ameye L, Gebhart M, de Saint-Aubain de Somerhausen N, Beauvois S, Awada A, Piccart-Gebhart M, Gil T
Année : 2018
Journal : Int J cancer and oncology
Volume : 5(1)
Pages : 26-34

Calcitonin and Carcinoembryonic Antigen for the Diagnosis and Management of Medullary Thyroid Carcinoma. in : Luca Giovanella, Editor. Atlas of Thyroid and Neuroendocrine Tumor Markers. Springer

Auteurs : Costante G, Lalami Y, Jungels C, Awada A
Année : 2018
Journal : Book
Volume : -
Pages : 133-150

Precision oncology: as much expectations as limitations.

Auteurs : Vasconcellos VF, Colli LM, Awada A, de Castro Junior G
Année : 2018
Journal : Ecancermedicalscience
Volume : 12
Pages : ed86

Risk factors for the development of brain metastases in patients with HER2-positive breast cancer.

Auteurs : Maurer C, Tulpin L, Moreau M, Dumitrescu C, de Azambuja E, Paesmans M, Nogaret JM, Piccart-Gebhart M, Awada A
Année : 2018
Journal : ESMO Open
Volume : 3
Pages : e000440

Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.

Auteurs : Campone M, Im SA, Iwata H, Clemons M, Ito Y, Awada A, Chia S, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Cortés J, De Laurentiis M, Arteaga CL, Jiang Z, Jonat W, Le Mouhaër S, Sankaran B, Bourdeau L, El-Hashimy M, Sellami D, Baselga J
Année : 2018
Journal : Eur J Cancer
Volume : 103
Pages : 147-154

Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.

Auteurs : Krayem M, Najem A, Journe F, Morandini R, Sales F, Awada A, Ghanem G
Année : 2018
Journal : Oncotarget
Volume : 9
Pages : 31888-31903

Tackling the challenges of brain metastases in solid tumors.

Auteurs : Kotecki N, Awada A
Année : 2018
Journal : Curr Opin Oncol
Volume : 30
Pages : 330-331

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.

Auteurs : Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M
Année : 2018
Journal : Bull Cancer
Volume : 105
Pages : 842-846

Therapy of breast cancer brain metastases: challenges, emerging treatments and perspectives.(article)

Auteurs : Kotecki N, Lefranc F, Devriendt D, Awada A
Année : 2018
Journal : Ther Adv Med Oncol
Volume : 10
Pages : 1758835918780312

Retroperitoneal mixed malignant mullerian tumor : exceptional localisation and prognosis.

Auteurs : El Hachem G, Jungels C, Larsimont D, Awada A
Année : 2018
Journal : Rev Med Brux
Volume : 39
Pages : 146-149

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.

Auteurs : Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, Aftimos P, Bekradda M, Rezai K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C
Année : 2018
Journal : J Clin Oncol
Volume : 36
Pages : 3007-3014

Change in topoisomerase 1 (Top1) positive circulating tumor cells impacts overall survival in patients with advanced breast cancer after treatment with etirinotecan pegol.

Auteurs : Rugo HS, Cortes J, Awada A, OShaughnessey J, Twelves CJ, Im SA, Hannah A, Lu L, Sy S, Caygill K, Zajchowski DA, Davis DW, Tagliaferri MA, Hoch U, Perez EA
Année : 2018
Journal : Clin Cancer Res
Volume : 24(14)
Pages : 3348-3357

Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer.

Auteurs : Traina TA, Miller K, Yardley DA, Eakle J, Schwartzberg LS, OShaughnessy J, Gradishar W, Schmid P, Winer E, Kelly C, Nanda R, Gucalp A, Awada A, Garcia-Estevez L, Trudeau ME, Steinberg J, Uppal H, Tudor IC, Peterson A, Cortes J
Année : 2018
Journal : J Clin Oncol
Volume : 36(9)
Pages : 884-890

Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer.

Auteurs : Basaran G, Twelves C, Diéras V, Cortés J, Awada A
Année : 2018
Journal : Cancer Treat Rev
Volume : 63
Pages : 144-155

New Drug Combination Strategies in Melanoma: Current Status and Future Directions.

Auteurs : Najem A, Krayem M, Perdrix A, Kerger J, Awada A, Journe F, Ghanem G
Année : 2017
Journal : Anticancer Res
Volume : 37
Pages : 5941-5953

Hepatoid Adenocarcinoma of the Stomach: A Challenging Diagnostic and Therapeutic Disease through a Case Report and Review of the Literature.

Auteurs : Fakhruddin N, Bahmad HF, Aridi T, Yammine Y, Mahfouz R, Boulos F, Awada A, Farhat F
Année : 2017
Journal : Front Med (Lausanne)
Volume : 4
Pages : 164